Fulgent Genetics Reports Widened Losses, Negative Operating Cash Flow, and Anticipates Significant 2026 Revenue Decline from Key Customer

summarizeSummary

Fulgent Genetics reported increased net losses and a shift to negative operating cash flow in 2025, with a significant revenue decline expected in 2026 due to a major customer insourcing services. The company also faces ongoing legal investigations related to past billing practices.

check_boxKey Events

• Financial Performance Deterioration

  Net loss widened to $60.5 million in 2025 from $42.7 million in 2024, an increase of 42%. Operating loss also increased by 23% to $91.1 million.

• Shift to Negative Operating Cash Flow

  The company used $101.6 million in cash from operating activities in 2025, a significant reversal from the $21.1 million generated in 2024, indicating increased cash burn.

• Significant 2026 Revenue Headwind

  Management expects reduced revenues in 2026, especially in the first half, from a single large customer that accounted for 22% ($70.8 million) of total revenue in 2025, as this customer begins performing tests internally.

• Major Legal and Regulatory Investigations

  Fulgent Genetics is subject to ongoing DOJ Civil Investigative Demands (CIDs) related to False Claims Act allegations (medically unnecessary testing, improper billing, Anti-Kickback Statute, Stark Law violations) and an HRSA audit concerning $548.9 million in COVID-19 test reimbursements. A qui tam complaint related to COVID-19 testing was unsealed and dismissed without prejudice in February 2026, but can be refiled.

auto_awesomeAnalysis

Fulgent Genetics' annual report reveals a challenging financial landscape with a substantial increase in net loss to $60.5 million in 2025 from $42.7 million in 2024, and a significant shift to negative operating cash flow, using $101.6 million in 2025 compared to generating $21.1 million in 2024. The company projects a material revenue decline in 2026, particularly in the first half, due to a major customer (representing 22% of 2025 revenue) bringing testing services in-house. This financial deterioration is compounded by ongoing DOJ Civil Investigative Demands and an HRSA audit related to past COVID-19 testing reimbursements, posing considerable legal and financial risks. While strategic acquisitions and therapeutic R&D efforts are underway, the immediate financial outlook and regulatory overhang present significant concerns for investors.